MedWatch

European innovation initiative puts Novo, Sanofi, and Eli Lilly in the same room

Novo Nordisk is participating in a public-private, European initiative, under which the firm has to share data with some of its biggest competition. Being a partner and a competitor can be a balancing act, according to Novo VP Matthias Müllenborn.

Matthias Müllenborn, vice president for study programs, patients and partnerships at Novo Nordisk | Photo: Ulrich Quistgaard

Novo Nordisk sees clear advantages from being part of the new public-private, European partnership, dubbed the Innovative Health Initiative (IHI), which brings the EU and the life science industry closer to each other with a budget of EUR 2.4bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs